{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T16:32:42Z","timestamp":1754152362765,"version":"3.41.2"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,21]]},"DOI":"10.7759\/cureus.88475","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T05:01:27Z","timestamp":1753160487000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Clinical Experience With Monthly Faricimab for Treatment-Na\u00efve Diabetic Macular Edema: A Case Series From an Indian Tertiary Care Center"],"prefix":"10.7759","author":[{"given":"Anand K","family":"Bukke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uma","family":"Ganganakurthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajalingam","family":"Vairagyam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keerthi R","family":"Vontela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00603-y","article-title":"Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights","volume":"10","author":"Sakini AS","year":"2024","unstructured":"Sakini AS, Hamid AK, Alkhuzaie ZA, et al.. Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights. Int J Retina Vitreous. 2024, 10:83. 10.1186\/s40942-024-00603-y","journal-title":"Int J Retina Vitreous"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2025.01.022","article-title":"Twenty-year trends in prevalence and incidence of diabetic retinal disease","volume":"132","author":"VanderBeek BL","year":"2025","unstructured":"VanderBeek BL, Yu Y, Cardillo S, Hubbard R. Twenty-year trends in prevalence and incidence of diabetic retinal disease. Ophthalmology. 2025, 132:767-774. 10.1016\/j.ophtha.2025.01.022","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00544-6","article-title":"Recommendations for diabetic macular edema management by retina specialists and large language model-based artificial intelligence platforms","volume":"10","author":"Choudhary A","year":"2024","unstructured":"Choudhary A, Gopalakrishnan N, Joshi A, et al.. Recommendations for diabetic macular edema management by retina specialists and large language model-based artificial intelligence platforms. Int J Retina Vitreous. 2024, 10:22. 10.1186\/s40942-024-00544-6","journal-title":"Int J Retina Vitreous"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2024.07.006","article-title":"Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration","volume":"69","author":"Vujosevic S","year":"2024","unstructured":"Vujosevic S, Lupidi M, Donati S, Astarita C, Gallinaro V, Pilotto E. Role of inflammation in diabetic macular edema and neovascular age-related macular degeneration. Surv Ophthalmol. 2024, 69:870-881. 10.1016\/j.survophthal.2024.07.006","journal-title":"Surv Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S383101","article-title":"Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis","volume":"16","author":"Xu M","year":"2022","unstructured":"Xu M, Fan R, Fan X, Shao Y, Li X. Progress and challenges of anti-VEGF agents and their sustained-release strategies for retinal angiogenesis. Drug Des Devel Ther. 2022, 16:3241-3262. 10.2147\/DDDT.S383101","journal-title":"Drug Des Devel Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S231801","article-title":"Angiopoietins as potential targets in management of retinal disease","volume":"15","author":"Khanani AM","year":"2021","unstructured":"Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, Singh RP. Angiopoietins as potential targets in management of retinal disease. Clin Ophthalmol. 2021, 15:3747-3755. 10.2147\/OPTH.S231801","journal-title":"Clin Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06531-9","article-title":"Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes","volume":"262","author":"Agostini H","year":"2024","unstructured":"Agostini H, Abreu F, Baumal CR, et al.. Faricimab for neovascular age-related macular degeneration and diabetic macular edema: from preclinical studies to phase 3 outcomes. Graefes Arch Clin Exp Ophthalmol. 2024, 262:3437-3451. 10.1007\/s00417-024-06531-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref8","unstructured":"Csaky KG. Dual inhibition of Ang-2 and VEGF-A with faricimab: advances in understanding and treatment of retinal diseases. (2021). https:\/\/medically.roche.com\/content\/dam\/pdmahub\/restricted\/ophthalmology\/angiogenesis-2021\/Angiogenesis-2021-presenta...."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02675-y","article-title":"Comparative efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: a systematic literature review and network meta-analysis","volume":"40","author":"Watkins C","year":"2023","unstructured":"Watkins C, Paulo T, B\u00fchrer C, Holekamp NM, Bagijn M. Comparative efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: a systematic literature review and network meta-analysis. Adv Ther. 2023, 40:5204-5221. 10.1007\/s12325-023-02675-y","journal-title":"Adv Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S502033","article-title":"Clinical evaluation of faricimab in real-world diabetic macular edema in India - a multicenter observational study","volume":"19","author":"Chakraborty D","year":"2025","unstructured":"Chakraborty D, Das S, Maiti A, et al.. Clinical evaluation of faricimab in real-world diabetic macular edema in India - a multicenter observational study. Clin Ophthalmol. 2025, 19:269-277. 10.2147\/OPTH.S502033","journal-title":"Clin Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong TY","year":"2024","unstructured":"Wong TY, Haskova Z, Asik K, et al.. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials. Ophthalmology. 2024, 131:708-723. 10.1016\/j.ophtha.2023.12.026","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-024-00525-9","article-title":"Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME","volume":"10","author":"Penha FM","year":"2024","unstructured":"Penha FM, Masud M, Khanani ZA, et al.. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retina Vitreous. 2024, 10:5. 10.1186\/s40942-024-00525-9","journal-title":"Int J Retina Vitreous"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff CC","year":"2022","unstructured":"Wykoff CC, Abreu F, Adamis AP, et al.. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet Lond Engl. 2022, 399:741-755. 10.1016\/S0140-6736(22)00018-6","journal-title":"Lancet Lond Engl"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni J","year":"2019","unstructured":"Sahni J, Patel SS, Dugel PU, et al.. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019, 126:1155-1170. 10.1016\/j.ophtha.2019.03.023","journal-title":"Ophthalmology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/369692-real-world-clinical-experience-with-monthly-faricimab-for-treatment-nave-diabetic-macular-edema-a-case-series-from-an-indian-tertiary-care-center","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T05:01:32Z","timestamp":1753160492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/369692-real-world-clinical-experience-with-monthly-faricimab-for-treatment-nave-diabetic-macular-edema-a-case-series-from-an-indian-tertiary-care-center"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.88475","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,7,21]]}}}